Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Trial Profile

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary) ; Tocilizumab
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 19 Dec 2018 Results assessing the safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis in the ASCERTAIN and Study 1309, published in the Rheumatology
    • 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
    • 16 Jun 2018 Results of pooled data from two trials (NCT02404558 and NCT02097524), were presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top